News
James B. Bell
- September 12, 2023
Avalo Therapeutics saw a significant boost in its shares, rising 53% to 13 cents, following the announcement of the sale of its rights, title, and interest in assets related to AVTX-801 D-galactose, AVTX-802 D-mannose, and AVTX-803 L-fucose to AUG Therapeutics.
Stock Performance
Avalo Therapeutics' stock experienced a low point of 8 cents on Monday, marking a 97% decrease over the past 12 months.
Terms of the Deal
As part of the agreement, AUG Therapeutics will make an upfront payment of $150,000 in addition to a contingent milestone payment of $15 million for each compound. However, this milestone payment will only be triggered if the first approval by the Food and Drug Administration (FDA) is granted for an indication other than a rare pediatric disease.
Furthermore, AUG Therapeutics will also be responsible for assuming up to $150,000 of certain liabilities incurred prior to the date of the purchase agreement. Additionally, all costs related to the 800 Series will be taken over by AUG Therapeutics.
Closing of the Transaction
The transaction is scheduled to conclude in the fourth quarter of 2023.
PREVIOUS POST
Oracle Shares Slump After Disappointing Guidance
Related Articles
Mercedes-Benz Group to Report Q2 Results
Mercedes-Benz Group is set to release its second-quarter results, with an estimated sales increase and growth in EBIT. Learn about the van business performance,...
B. Riley Financial Denies Allegations
B. Riley Financial denies involvement in alleged misconduct at Prophecy Asset Management, with internal review confirming innocence. Response leads to shares ri...
Orsted Enters First Solar Project in the U.K.
Orsted announces its entry into the U.K.'s solar sector by collaborating with PS Renewables to develop the One Earth Solar Farm, aligning with the U.K. governme...